QUOTE AND NEWS
newratings.com  Jul 21  Comment 
WASHINGTON (dpa-AFX) - Medidata (MDSO), a provider of cloud-based solutions for clinical research in life sciences, said second-quarter net income slipped to $1.5 million, or $0.03 per share, from $2.3 million, or $0.04 per share, in the second...
Benzinga  Jul 21  Comment 
Medidata (NASDAQ: MDSO) Validic today announced a collaboration to propel connectivity and innovation in clinical research by expanding access to patient-generated data from a broad range of consumer and medical grade...
Benzinga  Apr 28  Comment 
Analysts at Jefferies downgraded Medidata Solutions Inc (NASDAQ: MDSO) from Buy to Hold. The price target for Medidata Solutions has been raised from $52.00 to $55.00. Medidata Solutions shares have gained 55.46 percent over the past 52...
Benzinga  Apr 28  Comment 
Motley Fool  Apr 23  Comment 
Robust revenue and EPS helped propel Medidata Solutions Inc. shares higher today.
SeekingAlpha  Apr 1  Comment 
Benzinga  Mar 24  Comment 
In a report published Tuesday, Stifel analyst Steven Rubis reiterated a Buy rating on Medidata Solutions, Inc. (NASDAQ: MDSO), and raised the price target from $55.00 to $60.00. In the report, Stifel noted, "On Tuesday, March 17, Medidata...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS
Medidata Solutions (NASDAQ:MDSO) sells a software platform called Medidata Rave that helps biotech and pharmaceutical companies enhance the efficiency of their clinical development processes.[1] It achieves this by integrating electronic data capture (EDC) with a clinical data management system (CDMS) in a single product.
Medidata Rave is a comprehensive platform that replaces traditional paper-based methods of capturing and managing clinical data.
Medidata Rave is a comprehensive platform that replaces traditional paper-based methods of capturing and managing clinical data.
The company also sells a protocol authoring tool (Medidata Designer), a grant management system (Medidata Grant Manager) and a CRO contracting platform (Medidata CRO Contractor). In 2007, 2008 and the first quarter of 2009, the company's top five customers by revenue were Johnson & Johnson, AstraZeneca, Amgen, Astellas Pharma and Takeda Pharmaceutical.[1]

Medidata's initial public offering (IPO) of stock is scheduled for 18 June 2009. It plans to sell 6.3 million shares at between $11 and $12 per share. In 2008, the company had $106 million in total revenues, up 67.9% from $63.0 million in 2007. However, it still made a net loss of $18.3 million, down 22.8% from the $23.7 million net loss made in 2007.[2] In the same year, 69% of revenues came from customers in the United States, 21% from Europe and 10% from Asia (including Australia). In the first quarter of 2009, the company had $33.6 million in total revenues, up 60.2% from $21.0 million in the same quarter of the 2008.[2] It also had $1.7 million in net income, up 120% from the $8.6 million net loss made in 2007. Existing investors in the company include Insight Venture Partners (33.9%), chief executive officer and chairman Tarek Sherif (9.0%), president and director Glen M. de Vries (9.0%) and Milestone Venture Partners (7.6%).

References

  1. 1.0 1.1 Business, 2009 MDSO S-1/A
  2. 2.0 2.1 Selected Consolidated Financial Information, 2009 MDSO S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki